Podcast | Stem Cells
Today we have John Arnone CEO and Chairman of American CryoStem Corporation
Over the past eight years American CryoStem has strategically transitioned from a developmental stage company in an early market environment to a fully operational,commercial stem cell processing and cryo-banking facility supporting the rapidly expanding
Regenerative Medicine Industry.
FreshBooks is offering a month of unrestricted use to all of our listeners totally free right now…. and you don’t need a credit card for the trial.
● To claim your free month, go to www.FreshBooks.com/PHIL
…. and enter POSITIVE PHIL in the “How Did You Hear About Us?” section.
The company’s cellular processing platform was developed to allow the company, partners and other cellular therapy developers to quickly develop products without having to rediscover and recreate the necessary underlying technology (collect-process-store) for each new product.
Founded in 2008, American CryoStem (“CRYO”) is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies for the fields of Regenerative and Personalized Medicine. The Company is a developer, marketer and global licensor of adipose tissue based stem cell technologies and related proprietary laboratory services. The Company operates a state-of-art, FDA-registered, clinical laboratory in Princeton, New Jersey and licensed laboratories in Hong Kong, China, and Tokyo, Japan, dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs)
The Company’s current strategy is to allow individuals, physicians and international licensees to utilize CRYOs infrastructure and patented products to tap into the power of stem cells to prevent and treat disease, regenerate damaged or aged tissue, and to provide cosmetic applications based on technologies developed in-house and through collaborative arrangements with other biotech companies. The Company utilizes its comprehensive platform to support multiple cell lines related to gender, age, nationality and disease which allow clinicians and researchers to pursue cellular therapies and drug discovery research.